SAFC Installs Continuous-Flow Reactor - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

SAFC Installs Continuous-Flow Reactor

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 6

SAFC Commercial, the custom manufacturing services business unit of Sigma-Aldrich, has installed a new commercial-scale continuous flow reactor at its Sheboygan, Wisconsin facility with capacity to produce up to 150 kg of product per day. Now fully operational, the reactor is complemented by a smaller pilot-scale continuous flow reactor that is being fabricated at the nearby Milwaukee, Wisconsin facility to carry out process optimization studies and manufacturing capability of up to 30 kg of product per day.
 
"These capabilities give customers access to products synthesized through reactions that were previously impractical or impossible to do with a conventional batch platform," said Andreas Weiler, director of global strategic marketing for SAFC, in a press release. "The reactors will allow SAFC to develop or scale up flow reactions for customers, eliminating the need for customers to install in-house flow capacity. This is also a much greener technology and substantially reduces the amount of chemicals and solvents employed in reactions."
 
Continuous flow manufacturing is a lean manufacturing platform that provides customers access to as little or as much of a product as needed. The nature of this technique offers safer, seamless scale-up of a wider array of reactions compared to the batch platform. Additionally, this technique may aid customers in achieving process control, while helping to eliminate batch failures and minimize risks associated with handling hazardous chemicals.

Source: Sigma-Aldrich

 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here